MAPT and early-onset autosomal dominant Alzheimer disease: These actions collectively reduce Aβ and tau pathology, promote neuronal survival, and improve cognitive function, highlighting the prospective probable therapeutic potential of CV and its niosomal formulation in neurodegenerative disorders such as Alzheimer’s disease.